Trials / Active Not Recruiting
Active Not RecruitingNCT05095519
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
Hepatocellular Carcinoma Imaging Using PSMA PET/CT - a Prospective Pilot Trial
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Peter MacCallum Cancer Centre, Australia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).
Detailed description
A total of 30 patients will be recruited in this prospective pilot study who have HCC on imaging criteria (LI-RADS 5) for surgical resection, or patients with indeterminate liver lesions (LI-RADS 3 or 4) planned for liver biopsy. 18F-DCFPYL PSMA PET/CT will be performed prior to the planned surgery or liver biopsy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-DCFPyL | 18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection |
Timeline
- Start date
- 2021-09-08
- Primary completion
- 2026-03-08
- Completion
- 2026-09-08
- First posted
- 2021-10-27
- Last updated
- 2025-07-16
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05095519. Inclusion in this directory is not an endorsement.